Abstract
PD-(L)1×VEGF bispecific antibodies integrate immune checkpoint blockade and VEGF inhibition within a single molecule, offering a potential strategy to overcome angiogenesis-associated immune resistance. At the 2026 ASCO Annual Meeting, the randomized phase 3 HARMONi-6 trial demonstrated an overall survival benefit with ivonescimab plus chemotherapy over tislelizumab plus chemotherapy in previously untreated advanced squamous non-small cell lung cancer (NSCLC), extending survival evidence to an active PD-1–based first-line comparator. Exploratory phase 2 studies of pumitamig, SSGJ-707, and HB0025 reported encouraging activity in first-line NSCLC, while phase 1 and 2 studies of IMM2510 and ivonescimab-based regimens suggested activity after prior immunotherapy. Smaller exploratory studies also reported activity in perioperative head and neck cancer, colorectal cancer, endometrial cancer, and mucosal melanoma. Collectively, these findings highlight the clinical potential of PD-(L)1×VEGF bispecific antibodies, with the strongest evidence in first-line squamous NSCLC and broader applications remaining hypothesis-generating. Future development should prioritize predictive biomarkers, resistance mechanisms, optimal treatment sequencing, and careful assessment of immune-related and VEGF-associated toxicities.
Keywords: PD-(L)1×VEGF, Bispecific antibodies, Solid tumors, Immunotherapy, ASCO 2026
To the editor,
Immune checkpoint inhibitors have reshaped the treatment landscape of multiple solid tumors, yet resistance remains a major challenge. Beyond angiogenesis, vascular endothelial growth factor (VEGF) contributes to immune escape by disrupting tumor vasculature and limiting immune-cell infiltration, providing a strong rationale for combined programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1) and VEGF blockade [1]. Bispecific antibodies (BsAbs) co-targeting PD-1 or PD-L1 and VEGF integrate both activities within a single molecule, potentially coupling immune reactivation with vascular normalization and coordinated dual-target engagement. These PD-(L)1×VEGF BsAbs differ in checkpoint targeting, with PD-1 blockade also interrupting PD-L2 signaling, and in VEGF specificity, ranging from VEGF-A-selective binding to VEGFR1-derived ligand traps. Preclinical studies of ivonescimab further demonstrated reciprocal cooperative binding between PD-1 and VEGF-A, whereby engagement of either target enhanced binding to the other and strengthened functional blockade of both pathways [2]. Here, we summarize selected prospective studies of PD-(L)1×VEGF BsAbs presented at ASCO 2026 that reported efficacy outcomes, including monotherapy and combination regimens. Retrospective and real-world studies and trials-in-progress without efficacy data were excluded. Key agent properties and clinical results are summarized in Tables 1 and 2.
Table 1.
Key properties of PD-(L)1×VEGF bispecific antibodies represented in prospective studies at the 2026 ASCO Annual Meeting
| Agent | Format/ targets | Key features | Clinical development stage | Indications studied | Ref |
|---|---|---|---|---|---|
| Ivonescimab | Tetravalent, Fc-silent BsAb; PD-1 × VEGF-A | Cooperative binding design; Fc-silent architecture | Phase 3 in NSCLC; phase 2 in SCLC and other solid tumors | NSCLC; SCLC; HNSCC; CRC; mucosal melanoma | [3–7] |
| Pumitamig (BNT327/BMS-986545) | BsAb; PD-L1 × VEGF-A | PD-L1-directed format | Phase 2 dose optimization in global Phase 2/3 program | First-line NSCLC | [8] |
| SSGJ-707 (PF-08634404) | Fully human IgG4 BsAb; PD-1 × VEGF | Fully human IgG4 design | Phase 2 monotherapy data; Phase 3 studies initiated | First-line NSCLC; advanced/recurrent EC | [9, 10] |
| HB0025 | BsAb fusion protein; PD-L1 × VEGF | Receptor-domain VEGF trap | Phase 2 data; Phase 3 studies initiated | First-line SQ and NSQ NSCLC | [11] |
| IMM2510 (palverafusp alfa) | BsAb fusion protein; PD-L1 × VEGF | Dual-pathway fusion protein | Phase 1 dose-escalation data; Phase 3 planned | Advanced solid tumors | [12] |
Abbreviations: BsAb, bispecific antibody; CRC, colorectal cancer; EC, endometrial cancer; Fc, fragment crystallizable; HNSCC, head and neck squamous cell carcinoma; IgG4, immunoglobulin G4; NSCLC, non-small cell lung cancer; NSQ, nonsquamous; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; SCLC, small-cell lung cancer; SQ, squamous; VEGF, vascular endothelial growth factor
Table 2.
Prospective clinical results of PD-(L)1×VEGF bispecific antibodies reported at the 2026 ASCO Annual Meeting
| Trial (abstract no.; presentation) | Study phase/design; comparator | Population | Regimen | Follow-up maturity | Key efficacy results | Key safety results |
|---|---|---|---|---|---|---|
| HARMONi-6 (LBA4; Plenary) | Phase 3, randomized, double-blind; interim OS analysis; active control: tislelizumab + same chemotherapy. | Previously untreated advanced SQ NSCLC (n = 532) | Ivonescimab + carboplatin/paclitaxel | Median follow-up 21.4 months at OS analysis | Median OS 27.9 vs. 23.7 months; HR 0.66 (95% CI 0.50–0.87) | Grade ≥ 3 TRAE: 184/266 (69%) vs. 156/265 (59%); grade ≥ 3 hemorrhage: 7/266 (3%) vs. 2/265 (1%) |
| ROSETTA Lung-02 (8513; Rapid Oral) | Phase 2, randomized dose comparison; no standard-care control. | First-line NSCLC; 44 enrolled, 43 safety-evaluable, 40 efficacy-evaluable | Pumitamig + chemotherapy at two dose levels | Median treatment duration 4.5 months; median follow-up not reported; response duration immature | Confirmed ORR 21/40 (52.5%); lower-dose NSQ 8/11 (72.7%) and SQ 9/11 (81.8%) ORRs were unconfirmed | Grade ≥ 3 pumitamig-related TRAE 8/43 (18.6%); grade ≥ 3 irAE 1/43 (2.3%); one grade 3 bleed |
| NCT06361927 (8514; Rapid Oral) | Phase 2, single-arm; no comparator. | First-line PD-L1-positive NSCLC | SSGJ-707 monotherapy | Median follow-up 15.2 months | Confirmed ORR 23/34 (67.6%; 95% CI 49.5–82.6); median PFS 12.4 months | Across-dose grade ≥ 3 TRAE 35/83 (42.2%); grade ≥ 3 VEGF-related events 15/83 (18.1%) |
| NCT06758557 (8574; Poster) | Phase 2, single-arm; no comparator. | First-line SQ/NSQ NSCLC; 125 treated and 119 efficacy-evaluable | HB0025 + chemotherapy | Median follow-up 10.55 months | ORR 49/58 (84.5%) in SQ and 40/61 (65.6%) in NSQ; median PFS 12.62 and 14.65 months, respectively | Grade ≥ 3 proteinuria 8.8%, hypertension 6.4%, hemorrhage 4.0%, and thromboembolism 4.0%; discontinuation 6/125; treatment-related death 2/125 |
| NCT05972460 (8580; Poster) | Phase 1, single-arm; no comparator. | IO-pretreated SQ NSCLC; 32 treated and 22 efficacy-evaluable | IMM2510 monotherapy | Median follow-up 8.3 months | ORR 6/22 (27.3%); DCR 18/22 (81.8%); median DOR 11.1 months; median PFS 9.4 months | Grade ≥ 3 TRAE 12/32 (37.5%); one discontinuation; no treatment-related death |
| NCT06478043 (8007; Oral) | Phase 2, single-arm; no comparator. | SCLC after first-line chemoimmunotherapy (n = 60) | Ivonescimab + liposomal irinotecan | Median follow-up 7.3 months | 6-month PFS 72.0%; ORR 37/60 (61.7%); DCR 55/60 (91.7%); median PFS 9.8 months | Grade ≥ 3 TRAE 16/60 (26.7%); no treatment-related death |
| NCT06537011 (6014; Rapid Oral) | Phase 2, exploratory single-arm; no comparator. | Resectable locally advanced HNSCC; 36 enrolled, 34 radiologically evaluable, 30 resected | Ivonescimab + nab-paclitaxel/cisplatin for 3 cycles, then surgery; postoperative radiotherapy ± chemotherapy and ivonescimab maintenance | Survival follow-up not reported | Radiologic ORR 34/34 (100%); pathologic complete response 15/30 (50%); R0 resection 30/30 | Grade ≥ 3 events included pharyngeal fistula and transient transaminase elevation |
| NCT05382442 (3576; Oral) | Phase 2, randomized dose cohorts; no standard-care comparator. | First-line metastatic CRC; 49 treated and 48 efficacy-evaluable | Ivonescimab + modified FOLFOX6 at two dose levels | Median follow-up 7.5 months (20 mg/kg) and 7.1 months (10 mg/kg) | ORR 17/24 (70.8%) in each dose cohort; DCR 100% in each; 6-month PFS 95.2% and 84.8%; median PFS not reached | Grade ≥ 3 ivonescimab-related events 40.0% and 33.3% by dose |
| NCT06522828 (5627; Poster) | Phase 2, noncomparative dose cohorts; no active control. | First-line advanced/recurrent EC; 32 treated, with 14 and 15 efficacy-evaluable by dose | SSGJ-707 + carboplatin/paclitaxel | Median follow-up not reported; median treatment duration 5.6 months; median PFS and OS not reached | Confirmed ORR 12/14 (85.7%) and 12/15 (80.0%) | Grade ≥ 3 TRAE 22/32 (68.8%); VEGF-associated fistula/perforation reported |
| NCT06424626 (9516; Rapid Oral) | Phase 1b, nonrandomized cohorts; cadonilimab + axitinib reference cohort (no randomized control). | Metastatic mucosal melanoma; 28 patients overall, including 14 in the ivonescimab cohort | Ivonescimab + axitinib | Median follow-up 13 months | Cadonilimab + axitinib: ORR 5/14 (35.7%), DCR 64.3%, median PFS 5.8 months; ivonescimab + axitinib: ORR 5/14 (35.7%), DCR 71.4%, median PFS 8.7 months | Across-study grade 3–4 TRAE 5/28 (17.9%); no treatment-related death |
Abbreviations: CI, confidence interval; CRC, colorectal cancer; DCR, disease control rate; DOR, duration of response; EC, endometrial cancer; FOLFOX6, leucovorin, fluorouracil, and oxaliplatin; HNSCC, head and neck squamous cell carcinoma; HR, hazard ratio; IO, immunotherapy; irAE, immune-related adverse event; NSCLC, non-small cell lung cancer; NSQ, nonsquamous; ORR, objective response rate; OS, overall survival; PD-L1, programmed death-ligand 1; PFS, progression-free survival; R0, microscopically margin-negative resection; SCLC, small-cell lung cancer; SQ, squamous; TRAE, treatment-related adverse event; VEGF, vascular endothelial growth factor. Efficacy and safety denominators are shown separately where they differ
Advances in first-line NSCLC
The phase 3 HARMONi-6 trial extended randomized overall survival (OS) evidence for this class into the first-line setting, using tislelizumab plus chemotherapy as an active PD-1–based comparator. Among 532 patients with previously untreated advanced squamous non-small cell lung cancer (NSCLC), ivonescimab (PD-1×VEGF-A) plus chemotherapy significantly improved median OS versus tislelizumab plus chemotherapy (27.9 vs. 23.7 months; hazard ratio [HR], 0.66; 95% confidence interval [CI], 0.50–0.87; one-sided P = 0.0017), without new safety signals [3]. Exploratory phase 2 studies extended investigation across additional agents. In the global phase 2 ROSETTA Lung-02 cohort, pumitamig (PD-L1×VEGF-A) plus chemotherapy achieved a confirmed objective response rate (ORR) of 52.5% [8]. SSGJ-707 (PD-1×VEGF-A) monotherapy achieved an ORR of 67.6% (95% CI, 49.5–82.6%) and median progression-free survival (PFS) of 12.4 months in the 10 mg/kg cohort with PD-L1 tumor proportion score ≥ 1% [9]. HB0025 (PD-L1×VEGF) plus chemotherapy yielded ORRs of 84.5% and 65.6% in squamous and nonsquamous disease, respectively. Grade ≥ 3 VEGF-related toxicities were observed, with 4.8% discontinuing HB0025 because of treatment-related adverse events and 1.6% experiencing treatment-related deaths [11]. Together, these data suggest that PD-(L)1×VEGF BsAbs may expand first-line treatment options in NSCLC, while their broader clinical impact will depend on achieving a favorable balance between efficacy and immune-related and VEGF-associated toxicities.
Activity in previously treated lung cancer
In a phase 1 study of IMM2510 (PD-L1×VEGF) monotherapy in immunotherapy-treated squamous NSCLC, the ORR was 27.3%, with a median duration of response of 11.1 months and median PFS of 9.4 months among 22 evaluable patients [12]. At the phase 2 level, ivonescimab plus liposomal irinotecan achieved an ORR of 61.7% (95% CI, 48.2–73.9%) and median PFS of 9.8 months in 60 patients with small-cell lung cancer (SCLC) progressing after first-line chemoimmunotherapy [4]. Grade ≥ 3 treatment-related adverse events occurred in 37.5% and 26.7%, respectively, with no treatment-related deaths. These early single-arm findings suggest potential activity after prior checkpoint inhibition, including in previously treated SCLC where therapeutic options remain limited.
Expansion beyond lung cancer
Exploratory phase 2 studies reported a pathologic complete response rate of 50.0% among 30 resected patients receiving neoadjuvant ivonescimab plus chemotherapy for head and neck squamous cell carcinoma [5], an ORR of 70.8% in each ivonescimab dose cohort with mFOLFOX6 (disease-control rate, 100%) in first-line metastatic colorectal cancer [6], and ORRs of 85.7% and 80.0% across two SSGJ-707 plus chemotherapy dose cohorts in endometrial cancer [10]. Phase Ib ivonescimab plus axitinib achieved an ORR of 35.7% and median PFS of 8.7 months in mucosal melanoma [7]. These hypothesis-generating findings highlight perioperative and relatively immunotherapy-insensitive settings for further investigation.
Taken together, the ASCO 2026 data position PD-(L)1×VEGF BsAbs as an emerging therapeutic class, with the most mature evidence currently in NSCLC. HARMONi-6 provides randomized phase 3 support in first-line squamous NSCLC, whereas evidence in other solid tumors remains largely exploratory and hypothesis-generating. Whether the bispecific format offers clinically meaningful advantages over conventional PD-(L)1 plus antiangiogenic combinations remains unresolved. Future development should focus on predictive biomarkers, mechanisms of resistance, optimal treatment sequencing, and the safety profile of combined immune and VEGF pathway inhibition.
Acknowledgements
Not applicable.
Abbreviations
- BsAb
Bispecific antibody
- CI
Confidence interval
- HR
Hazard ratio
- NSCLC
Non-small cell lung cancer
- ORR
Objective response rate
- OS
Overall survival
- PD-(L)1
Programmed cell death protein 1/programmed death-ligand 1
- PFS
Progression-free survival
- SCLC
Small-cell lung cancer
- VEGF
Vascular endothelial growth factor
Author contributions
Zegeng Chen and Rui Zhang designed the study. Zhao Wang, Chengcheng Guo, Xiaosi Yuan, and Qimei Guo contributed to the drafting and critical revision of the manuscript. All authors reviewed the manuscript and approved for its submission.
Funding
This work is supported by National Natural Science Foundation of China (82500236 to Zegeng Chen and U24A20679 to Zhao Wang).
Data availability
No datasets were generated or analysed during the current study.
Declarations
Ethics approval and consent to participate
The studies summarized were conducted in accordance with the Declaration of Helsinki. Ethics approval and consent to participate were not applicable to this summary, which used only published data.
Consent for publication
Not applicable.
Competing interests
The authors declare no competing interests.
Footnotes
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Zhao Wang and Chengcheng Guo contributed equally as co-first authors.
Contributor Information
Rui Zhang, Email: zhangrui139@tkhealthcare.com.
Zegeng Chen, Email: chenzg@sysucc.org.cn.
References
- 1.Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat reviews Clin Oncol. 2018;15(5):325–40. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Zhong T, Zhang L, Huang Z, Pang X, Jin C, Liu W, Du J, Yin W, Chen N, Min J, et al. Design of a fragment crystallizable-engineered tetravalent bispecific antibody targeting programmed cell death-1 and vascular endothelial growth factor with cooperative biological effects. iScience. 2025;28(3):111722. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Zhiwei C, Yang F, Luo Y, Sun L, Wu L, Han Z, Fan Y, Zhao Y, Li X, Xu H, et al. Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untreated advanced squamous non–small cell lung cancer: Overall survival results of the phase 3 HARMONi-6 trial. J Clin Oncol. 2026;44(17suppl):LBA4–4. [Google Scholar]
- 4.Fan Y, Chen K, Li H, Huang Z, Qin J, Yu X, Jin Y, Xu Y, He Q, Shao L, et al. Efficacy and safety of ivonescimab combined with liposomal irinotecan in patients with small-cell lung cancer (SCLC) progressing after first-line chemoimmunotherapy: A multicenter, phase 2 study. J Clin Oncol. 2026;44(16suppl):8007–8007. [Google Scholar]
- 5.Yang K, Zhang X, Wen L. Neoadjuvant ivonescimab (AK112, a PD-1/VEGF bispecific antibody) combined with nab-paclitaxel and cisplatin (AP) for resectable locally advanced head and neck squamous cell carcinoma (LA-HNSCC): An exploratory phase II study. J Clin Oncol. 2026;44(16suppl):6014–6014. [Google Scholar]
- 6.Berz D, Deng Y, Zhang J, Li Z, Yin M, Zhao J, Eckert KA, Paranthaman N, Yu X, Xia Y, et al. Ivonescimab (ivo) with oxaliplatin + fluorouracil (5-FU) + leucovorin calcium (mFOLFOX6) for patients (pts) with unresectable metastatic colorectal cancer (mCRC): A phase 2 study. J Clin Oncol. 2026;44(16suppl):3576–3576. [Google Scholar]
- 7.Mao L, Guo J, Si L. Cadonilimab or ivonescimab plus axitinib in metastatic mucosal melanoma: Results from a phase Ib trial. J Clin Oncol. 2026;44(16suppl):9516–9516. [Google Scholar]
- 8.Peters S, Lee Y, Erman M, Liu SV, Solomon BJ, Kato T, Lu S, Popat S, Gunaydin UM, Bartz R, et al. Phase 2 data from ROSETTA Lung-02, a global randomized phase 2/3 trial of pumitamig (PD-L1 × VEGF-A bsAb) + chemotherapy in 1L NSCLC. J Clin Oncol. 2026;44(16suppl):8513–8513. [Google Scholar]
- 9.Wu L, Yao J, Sun Y, Wang R, Li X, Chen B, Chu Q, Bu Q, Fang Y, Zhao J, et al. Updated results from a phase 2 trial of SSGJ-707 (PF-08634404), a PD-1/VEGF bispecific antibody, as monotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2026;44(16suppl):8514–8514. [Google Scholar]
- 10.Zhou Q, Long X, Wang D, Li L, Wang K, Wu Y, Weng G, Wu T, Sun Y, Li Q, et al. A phase 2 study evaluating SSGJ-707 (PF-08634404), a PD-1/VEGF bispecific antibody, + chemotherapy (chemo) in patients (pts) with first-line (1L) advanced/recurrent endometrial cancer (EC). J Clin Oncol. 2026;44(16suppl):5627–5627. [Google Scholar]
- 11.Wang L, Bai J, Liu B, Sun M, Wang Q, Gao S, Yu G, Yao Y, Shi J, Zang A-, et al. A phase II study of HB0025 (a PD-L1/VEGF bispecific antibody) in combination with chemotherapy as first-line treatment for non–small cell lung cancer (NSCLC). J Clin Oncol. 2026;44(16suppl):8574–8574. [Google Scholar]
- 12.Yu X, Wang P, Zhang Y, Wang R, Li X, Ma W, Song Z, Luo S, An S, Liu F-N, et al. Phase I study of IMM2510, a PD-L1/ VEGF bispecific antibody, in participants with advanced IO-treated SQ-NSCLC. J Clin Oncol. 2026;44(16suppl):8580–8580. [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
No datasets were generated or analysed during the current study.
